Regulus Therapeutics Stock (NASDAQ: RGLS)

Regulus Therapeutics

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Image26

News

Price Target

Markets

Analyst Ratings

Trading Ideas

BALL

BIRK

CHRW

CPRI

CRDO

ETSY

GTHX

RGLS

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday

document-428338_1280

Movers

Regulus Therapeutics announced positive results from its study related to the treatment of autosomal dominant polycystic kidney disease (AKPD).

What&#39;s Going On With Regulus Therapeutics Stock Monday?

Penny Stocks

Small Cap

Intraday Update

AFRM

AUUD

BTTX

CCTG

FUTU

FWBI

GIII

HEAR

HGAS

HOOD

IMRX

KPLT

MDGL

MOMO

NOVA

PANL

PATH

PERF

PIXY

PRST

PUYI

RAYA

RCMT

RMBL

SPRB

SPRO

TCON

UNCY

WIMI

WOOF

Shares of  Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Regulus Therapeutics Inc

REGULUS RES INC by Regulus Resources, Inc.

Regulus Resources Inc

Press Releases

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Earnings

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Cabaletta Bio

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Citius Oncology

Cue Biopharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

HilleVax

TuHURA Biosciences

IGM Biosciences

I-MAB

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Lexeo Therapeutics

MediciNova

OncoCyte

PepGen

Skye Bioscience

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Tenaya Therapeutics

Vigil Neuroscience

Zura Bio Limited - Class A Ordinary shares

Zura Bio

HC Wainwright & Co.

Oppenheimer

Canaccord Genuity

Jones Trading

Leerink Partners

Comments

Regulus Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga